Genomics

Dataset Information

3

Canadian Prostate Cancer Genome Network

ABSTRACT: Over 5 years, CPC-GENE will sequence the genomes of 350 intermediate risk prostate cancers to identify genetic signatures that differ in cancers that responded well to treatment compared with those that did not. CPC-GENE will also sequence multiple regions of prostate cancer from the same gland to determine if and how the genetic make-up of prostate cancer varies within an individual man’s prostate

PROVIDER: EGAS00001000900 | EGA |

REPOSITORIES: EGA

Json Xml
altmetric image

Publications

Genomic hallmarks of localized, non-indolent prostate cancer.

Fraser Michael M   Sabelnykova Veronica Y VY   Yamaguchi Takafumi N TN   Heisler Lawrence E LE   Livingstone Julie J   Huang Vincent V   Shiah Yu-Jia YJ   Yousif Fouad F   Lin Xihui X   Masella Andre P AP   Fox Natalie S NS   Xie Michael M   Prokopec Stephenie D SD   Berlin Alejandro A   Lalonde Emilie E   Ahmed Musaddeque M   Trudel Dominique D   Luo Xuemei X   Beck Timothy A TA   Meng Alice A   Zhang Junyan J   D'Costa Alister A   Denroche Robert E RE   Kong Haiying H   Espiritu Shadrielle Melijah G SM   Chua Melvin L K ML   Wong Ada A   Chong Taryne T   Sam Michelle M   Johns Jeremy J   Timms Lee L   Buchner Nicholas B NB   Orain Michèle M   Picard Valérie V   Hovington Helène H   Murison Alexander A   Kron Ken K   Harding Nicholas J NJ   P'ng Christine C   Houlahan Kathleen E KE   Chu Kenneth C KC   Lo Bryan B   Nguyen Francis F   Li Constance H CH   Sun Ren X RX   de Borja Richard R   Cooper Christopher I CI   Hopkins Julia F JF   Govind Shaylan K SK   Fung Clement C   Waggott Daryl D   Green Jeffrey J   Haider Syed S   Chan-Seng-Yue Michelle A MA   Jung Esther E   Wang Zhiyuan Z   Bergeron Alain A   Dal Pra Alan A   Lacombe Louis L   Collins Colin C CC   Sahinalp Cenk C   Lupien Mathieu M   Fleshner Neil E NE   He Housheng H HH   Fradet Yves Y   Tetu Bernard B   van der Kwast Theodorus T   McPherson John D JD   Bristow Robert G RG   Boutros Paul C PC  

Nature 20170109 7637

Prostate tumours are highly variable in their response to therapies, but clinically available prognostic factors can explain only a fraction of this heterogeneity. Here we analysed 200 whole-genome sequences and 277 additional whole-exome sequences from localized, non-indolent prostate tumours with similar clinical risk profiles, and carried out RNA and methylation analyses in a subset. These tumours had a paucity of clinically actionable single nucleotide variants, unlike those seen in metastat  ...[more]

Similar Datasets

Transcriptomics Canadian Prostate Cancer GEnome NEtwork – HuGene RNA expression
2017-04-15 | GSE56916 | GEO
Methylation profiling Association of self-identified race and genetic ancestry with the immunogenomic landscape of primary prostate cancer
2023-05-31 | GSE221219 | GEO
Transcriptomics Identifying actionable targets through integrative analyses of GEM model and human prostate cancer profiling [Agilent]
2015-02-20 | E-GEOD-61382 | biostudies-arrayexpress
Transcriptomics caArray_becic-00229: Gene expression analysis of prostate cancers
2015-05-06 | E-GEOD-68545 | biostudies-arrayexpress
Transcriptomics RNA sequencing of different GEMMs of prostate cancer
2023-06-09 | GSE202910 | GEO
Transcriptomics caArray_becic-00229: Gene expression analysis of prostate cancers
2015-05-06 | GSE68545 | GEO
Transcriptomics Functional enhancers at the gene-poor 8q24 cancer-linked locus
2009-12-18 | E-GEOD-19561 | biostudies-arrayexpress
Proteomics Human Prostate Tumor Subtypes
2022-02-28 | PXD002306 | Pride
Transcriptomics Molecular and pathological subtypes related to prostate cancer disparities and disease outcomes in African American and European American patients
2022-08-05 | GSE203338 | GEO
Transcriptomics Functional enhancers at the gene-poor 8q24 cancer-linked locus
2009-12-19 | GSE19561 | GEO